Lyon, France, March 21, 2022 – 6:00 p.m. CET – MaaT Pharma (EURONEXT: “MAAT” – the Company), a French late-stage biotechnology company, a pioneer in the development of drugs for the restoration of the intestinal microbiota to improve the survival of cancer patients, announces today the implementation of a liquidity contract with Kepler Cheuvreux relating to the management of its own shares admitted to trading on Euronext Paris.
To receive financial information from MaaT Pharma, send an e-mail to [email protected]